Single-Chain Immunotoxins Targeted to CD40 for the Treatment of Human B Lineage Hematologic Malignancies

References

• Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497
   PubMed Web of Science ®Google Scholar
• Siegall C.B., Wolff E.A., Gawlak S.L., Paul L., Chace D., Mixan B. Immunotoxins as cancer chemotherapeutic agents. Drug Dev. Res 1995; 34: 210–219
   Web of Science ®Google Scholar
• Brinkmann U., Pastan I. Immunotoxins against cancer. Biochim. Biophys. Acta 1994; 1198: 27–45
   PubMed Web of Science ®Google Scholar
• Kreitman R.J., Pastan I. Targeting Pseudomonas exotoxin to hematologic malignancies. Sem. Cancer Biol. 1995; 6: 297–306
   PubMed Web of Science ®Google Scholar
• Endo Y., Mitsui K., Motizuki M., Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes: the site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J. Biol. Chem. 1987; 262: 5908–5912
   PubMed Web of Science ®Google Scholar
• Carroll S.F., Collier R.J. Active site of Pseudomonas aeruginosa exotoxin A: glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J. Biol. Chem. 1987; 262: 8707–8711
   PubMed Web of Science ®Google Scholar
• Sausville E.A., Headlee D., Stetler-Stevenson JaffeE.S., Solomon D., Figg W.D., Herdt J., Kopp W.C., Rager H., Steinberg S.M., Ghetie V., Schnidler J., Uhr J., Wittes R.E., Vitetta E.S. Continuous infusion of the anti-CD22 immunotoxin lgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood 1995; 85: 3457–3465
   PubMed Web of Science ®Google Scholar
• Stone M.J., Sausville E.A., Fay J.W., Headlee D., Collins R.H., Figg W.D., Stetler-Stevenson M., Jain V., Jaffe E.S., Solomon D., Lush R.M., Senderowicz A., Ghetie V., Schindler J., Uhr J.W., Vitetta E.S. A phase I study of bolus versus continuous infusion of the anti-CD 19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996; 88: 1188–1197
   PubMed Web of Science ®Google Scholar
• Grossbard M.L., Lambert J.M., Goldmacher V.S., Spector N.L., Kinsella J., Eliseo L., Coral F., Taylor J.A., Blattler W.A., Epstein C.L., Nadler L.M. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J. Clin. Oncol 1993; 11: 726–737
   PubMed Web of Science ®Google Scholar
• Grossbard M.L., Freedman A.S., Ritz J., Coral F., Goldmacher V.S., Eliseo L., Spector N., Dear K., Lambert J.M., Blattler W.A., Taylor J.A., Nadler L.M. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 1992; 7: 576–585
   Google Scholar
• Pai L.H., Wittes R., Setser A., Willingham M.C., Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nature Med 1996; 2: 350–353
   PubMed Web of Science ®Google Scholar
• Friedman P.N., Chace D.F., Trail P.A., Siegall C.B. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. J. Immunol. 1993; 150: 3054–3061
   PubMed Web of Science ®Google Scholar
• Brinkmann U., Pai L.H., FitzGerald D.J., Willingham M., Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA 1991; 88: 8616–8620
   PubMed Web of Science ®Google Scholar
• Friedman P.N., McAndrew S.J., Gawlak S.L., Chace D., Trail P.A., Brown J.P., Siegall C.B. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. Cancer Res 1993; 53: 334–339
   PubMed Web of Science ®Google Scholar
• Kreitman R.J., Pastan I. Recombinant single-chain immunotoxins against T and B-cell leukemias. Leuk. Lymphoma 1994; 13: 1–10
   PubMed Web of Science ®Google Scholar
• Paulie S., Ehlin-Henriksson B., Mellstedt H., Koho H., Ben Aissa H., Perlmann P. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol. Immunother 1985; 20: 23–30
   PubMed Web of Science ®Google Scholar
• Clark E.A., Ledbetter J.A. Activation of human B-cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc. Natl. Acad. Sci. USA 1986; 83: 4494–4498
   PubMed Web of Science ®Google Scholar
• Banchereau J., Rousset F. Growing human B lymphocytes in the CD40 system. Nature 1991; 353: 678–679
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Gajl-Peczalska K., Myers D.E., Jaszcz W., Haissig S., Ledbetter J.A. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 1990; 76: 2449–2456
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C., Bataille R., Robillard N., Haroussequ J.-L., Rapp M.-J., Juge-Morineau N., Wijdenes J., Amiot M. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994; 84: 2597–2603
   PubMed Web of Science ®Google Scholar
• Ledbetter J.A., Clark E.A., Norris N.A., Shu G., Hellström I. Expression of a functional B-cell receptor CDw40 on carcinomas. Leukocyte Typing III: White Cell Differentiation Antigens, A.J. McMichael. Oxford University Press, OxfordUK 1987; 432–439
   Google Scholar
• Kiener P.A., Moran-Davis P., Rankin B.M., Wahl A.F., Aruffo A., Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J. Immunol. 1995; 155: 4917–4925
   PubMed Web of Science ®Google Scholar
• Galy A.H., Spits H. CD40 is functionally expressed on human thymic epithelial cells. J. Immunol. 1992; 149: 775–782
   PubMed Web of Science ®Google Scholar
• Caux C., Massacrier C., Vanbervliet B., Dubois B., Van Kooten C., Durand I., Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med 1994; 180: 1263–1272
   PubMed Web of Science ®Google Scholar
• Karmann K., Hughes C.C.W., Schechner J., Fanslow W.C., Pober J.S. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. USA 1995; 92: 4342–4346
   PubMed Web of Science ®Google Scholar
• Hollenbaugh D., Mischel-Petty N., Edwards C.P., Simon J.C., Denfeld R.W., Kiener P.A., Aruffo A. Expression of functional CD40 by vascular endothelial cells. J. Exp. Med 1995; 182: 33–40
   PubMed Web of Science ®Google Scholar
• Francisco J.A., Kiener P.A., Moran-Davis P., Ledbetter J.A., Siegall C.B. Cytokine activation sensitizes human monocytic and endothelial cells to the cytotoxic effects of an anti-CD40 immunotoxin. J. Immunol. 1996; 157: 1652–1658
   PubMed Web of Science ®Google Scholar
• Francisco J.A., Schreiber G.J., Comereski C.R., Mezza L.E., Warner G.L., Davidson T.J., Ledbetter J.A., Siegall C.B. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. Blood 1997; 89: 4493–4500
   PubMed Web of Science ®Google Scholar
• Clark E.A., Draves K.E. Activation of macaque T-cells and B-cells with agonistic monoclonal antibodies. Eur. J. Immunol. 1987; 17: 1799–1805
   PubMed Web of Science ®Google Scholar
• Ling N.R., MacLennan I., Mason D. B-cell and plasma cell antigens: new and previously defined clusters. Leukocyte Typing III: White Cell Differentiation Antigens, A.J. McMichael. Oxford University Press, OxfordUK 1987; 302–335
   Google Scholar
• Funakoshi S., Longo D.L., Beckwith M., Conley D.K., Tsarfaty G., Tsarfaty I., Armitage R.J., Fanslow W.C., Spriggs M.K., Murphy W.J. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994; 83: 2787–2794
   PubMed Web of Science ®Google Scholar
• Francisco J.A., Gilliland L.K., Stebbins M.R., Norris N.A., Ledbetter J.A., Siegall C.B. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. Cancer Res 1995; 55: 3099–3104
   PubMed Web of Science ®Google Scholar
• Kawata A., Yoshida M., Okazaki M., Yokota S., Barcos M., Seon B.K. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude models in the antitumor efficacy of monoclonal antibody. Cancer Res 1994; 54: 2688–2694
   PubMed Web of Science ®Google Scholar
• Ghetie M.-A., Richardson J., Tucker T., Jones D., Uhr J.W., Vitetta E.S. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int. J. Cancer 1990; 45: 481–485
   PubMed Web of Science ®Google Scholar
• Siegall C.B., Chace D., Mixan B., Garrigues U., Wan H., Paul L., Hellstrom I., Hellstrom K.E. In vitro, in vivo characterization of BR96 sFv-PE40, a single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats. J. Immunol. 1994; 152: 2377–2384
   PubMed Web of Science ®Google Scholar
• Braslawsky G.R., Edson M.A., Pearce W., Kaneko T., Greenfield R.S. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing. Cancer Res 1990; 50: 6608–6614
   PubMed Web of Science ®Google Scholar
• Siegall C.B., Liggitt D., Chace D., Tepper M.A., Fell H.P. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc. Natl. Acad. Sci. USA 1994; 91: 9514–9518
   PubMed Web of Science ®Google Scholar
• Siegall C.B., Liggitt D., Chace D., Mixan B., Sugai J., Davidson T., Steinitz M. Induction of vascular leak syndrome by the toxin component of Pseudomonas exotoxin based-immunotoxins: Essential role for Cox-2 and prevention with NSAIDs. Clinical Cancer Res 1997; 3: 339–345
   PubMed Web of Science ®Google Scholar
• Stirpe F., Barbieri L., Battelli M.G., Falasca A.I., Abbondanza A., Lorenzoni E., Stevens W.A. Bryodin, a ribosome-inactivating protein from the roots of Bryonia dioica L. (white bryony). Biochem J. 1986; 240: 659–665
   PubMed Web of Science ®Google Scholar
• Gawlak S.L., Neubauer M., Klei H.E., Chang C.Y., Einspahr H.M., Siegall C.B. Molecular, biological, and preliminary structural analysis of Bryodin 1, a ribosome-inactivating protein from the plant Bryonia dioica. Biochem 1997; 36: 3095–3103
   PubMed Web of Science ®Google Scholar
• Francisco J.A., Gawlak S.L., Miller M., Bathe J., Russell D., Chace D., Mixan B., Zhao L., Fell H.P., Siegall C.B. Expression and characterization of Bryodin 1 and a Bryodin 1-based single-chain anti-CD40 immunotoxin produced from tobacco tissue culture. Bioconj. Chem 1997; 8: 708–713
   PubMed Web of Science ®Google Scholar
• Siegall C.B., Gawlak S.L., Chace D., Wolff E.A., Mixan B., Marquardt H. Characterization of ribosome-inactivating proteins isolated from Bryonia dioica and their utility as carcinoma-reactive immunoconjugates. Bioconj. Chem. 1994; 5: 423–429
   PubMed Web of Science ®Google Scholar
• Francisco J.A., Gawlak S.L., Siegall C.B. Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein Bryodin 1. J. Biol. Chem. 1997; 272: 24165–24169
   PubMed Web of Science ®Google Scholar